| 本文言語 | English |
|---|---|
| ページ（範囲） | 200-202 |
| ページ数 | 3 |
| ジャーナル | Modern rheumatology |
| 巻 | 23 |
| 号 | 1 |
| DOI | |
| 出版ステータス | Published - 2013 1月 |
ASJC Scopus subject areas
- リウマチ学
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Modern rheumatology, Vol. 23, No. 1, 01.2013, p. 200-202.
研究成果: Letter › 査読
}
TY - JOUR
T1 - Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility in Japanese rheumatoid arthritis patients
AU - Suzuki, Taku
AU - Ikari, Katsunori
AU - Kawaguchi, Yasushi
AU - Yano, Koichiro
AU - Iwamoto, Takuji
AU - Kawamoto, Manabu
AU - Toyama, Yoshiaki
AU - Taniguchi, Atsuo
AU - Yamanaka, Hisashi
AU - Momohara, Shigeki
N1 - Funding Information: Acknowledgments We thank all of the DNA donors for making this study possible. We are grateful to Ms. Yukiko Kenyoshi for her technical efforts. We also appreciate Mr. Eisuke Inoue and other members of the Institute of Rheumatology, Tokyo Women’s Medical University for their efforts with the IORRA cohort. This work was supported by a Grant-in-Aid for Young Scientists (A) from the Japan Society for the Promotion of Science (20689029 to K.I.). The IORRA cohort was supported by unrestricted research grants from 40 pharmaceutical companies: Abbott Japan Co., Ltd., Asahikasei Kuraray Medical Co., Ltd., Asahikasei Pharma Corporation, Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Fine Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Dentsu, Sudler & Hennessey Inc., Eisai Co., Ltd., GlaxoSmithKline K.K., Hisamitsu Pharmaceutical Co., Inc., Janssen Pharmaceutical K.K. Japan Tobacco Inc., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Maruho Co., Ltd., Mitsu-bishi Chemical Medience Corporation, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Mundiphama K.K., Nippon Chemiphar Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi-Aventis K.K, Santen Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sekisui Medical Co., Ltd., Shionogi Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., Teijin Pharma Ltd., Torii Pharmaceutical Co., Ltd., UCB Japan Co., Ltd., and Zeria Pharmaceutical Co., Ltd. S.M. has received lecture fees and/or honoraria from Abbott Japan, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Santen Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Company Ltd. H.Y. has received lecture/consulting fees from Abbott Japan, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Hoffmann-La Roche, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., and Takeda Pharmaceutical Company Ltd.
PY - 2013/1
Y1 - 2013/1
KW - Autoimmune diseases
KW - CD226
KW - Gene
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84872486500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872486500&partnerID=8YFLogxK
U2 - 10.1007/s10165-012-0609-x
DO - 10.1007/s10165-012-0609-x
M3 - Letter
C2 - 22350639
AN - SCOPUS:84872486500
SN - 1439-7595
VL - 23
SP - 200
EP - 202
JO - Modern rheumatology
JF - Modern rheumatology
IS - 1
ER -